Drugs / MPLA-5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06449196 | Aug 2024 → Feb 2025 | HIV infectious disease | International AIDS Vaccine Initiative | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPLA-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06449196 ↗ |
| Known as | Monophosphoryl lipid A liposomes | “HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.” NCT06449196 ↗ |
| Route | Intramuscular | “adjuvant (IM) administered via bolus dosing” NCT06449196 ↗ |